Browse the evidence

GLP-1 medicines reduce food intake, body weight, insulin resistance and inflammation.

GLP-1 medicines can be considered for managing weight and metabolic health in patients with type 2 diabetes and obesity.

Incretin mimetics, including glucagon-like peptide-1 and glucose-dependent insulinotropic polypeptide agonists, are first-line treatment options for type 2 diabetes and obesity.

Healthcare professionals should consider these agents as primary treatment options for managing type 2 diabetes and obesity.

Semaglutide demonstrated superior efficacy with mean HbA1c reduction of 1.45% and weight loss of 1.44 kg.

Semaglutide is the most effective GLP-1 receptor agonist for improving glycemic control and promoting weight loss in T2DM patients.

Emerging oral therapies could complement or serve as alternatives to approved injectable treatments for long-term weight management.

Practitioners should consider these oral therapies as viable options alongside injectables.

Preconception weight optimization in women with obesity is important to reduce maternal and fetal risks.

Practitioners should prioritize weight management in women with obesity planning for pregnancy.

Average A1c decreased from 8.9% ± 1.3% to 7.6% ± 1.5% over 6 months (P < 0.001).

Clinicians may expect improvements in glycemic control with semaglutide in T2DM patients.

Body weight decreased from 123.9 ± 23.5 kg to 118.9 ± 22.9 kg over 6 months (P < 0.001).

Clinicians may observe weight loss in T2DM patients treated with semaglutide.

Newer anti-obesity medications such as semaglutide and tirzepatide have shown greater than 15% reduction in baseline weight.

Practitioners should consider these medications for patients seeking significant weight loss.

GLP-1 agonists are associated with favorable hemoglobin A1C levels and weight loss in type 1 diabetic patients.

GLP-1 agonists may be recommended for type 1 diabetes patients aiming for better glycemic control and weight management.

Tirzepatide treatment shows a potent glucose-lowering effect and promotes weight loss with minimal GI adverse effects.

Tirzepatide may be considered for patients needing effective glucose control and weight loss with fewer gastrointestinal side effects.

Semaglutide had substantial effects on multiple secondary alcohol-related and somatic outcomes.

Semaglutide may improve various aspects of health related to alcohol use disorder in addition to reducing drinking.

Semaglutide resulted in a similar reduction in body weight across frailty subgroups.

Semaglutide can be used effectively for weight management in patients with obesity-related HFpEF, regardless of frailty status.

Semaglutide 2.4 mg reduces body weight by an estimated mean change ranging from -9.40% to -16.42% in an East Asian population.

Practitioners can consider semaglutide 2.4 mg as an effective option for weight loss in East Asian adults with obesity.

GLP-1 receptor agonists or co-agonists have demonstrated substantial and sustained weight loss along with notable improvements in cardiometabolic markers.

Practitioners may consider GLP-1 receptor agonists as effective options for weight management and improving cardiometabolic health.

Combination strategies using endoscopic bariatric therapies (EBTs) and anti-obesity medications (AOMs) result in greater total-body weight loss than either modality alone.

Combining EBTs with AOMs may enhance weight loss outcomes for patients.

Lifestyle modifications can mitigate cancer risk associated with obesity.

Encouraging lifestyle changes can be a key strategy in cancer prevention efforts.

Novel medications such as GLP-1 agonists have demonstrated sustained weight loss in patients with obesity.

Practitioners can consider GLP-1 agonists as a treatment option for obesity.

The FDA authorizes the use of injectable semaglutide for the treatment of obesity.

Practitioners can consider semaglutide as an approved treatment option for obesity in the U.S.

A comprehensive approach is the best way to manage weight.

Practitioners should consider a multifaceted approach to obesity treatment.

Use of GLP‐1 or GLP‐1/GIP RA therapy after lung transplantation was effective at decreasing weight and improving hemoglobin A1c.

Practitioners can consider GLP-1 and GLP-1/GIP RA therapies for weight management and glycemic control in lung transplant patients.

Adding semaglutide to usual care in US adults without diabetes is projected to avert 358,400 major adverse cardiovascular events (MACE) at a cost of $148,100 per quality-adjusted life-year (QALY) gained.

Semaglutide may be a beneficial addition to treatment plans for eligible patients to reduce cardiovascular risks.

Tirzepatide is effective in glucose control and weight reduction.

Tirzepatide can be considered a viable option for improving glycemic control and aiding weight loss in diabetic patients.

A prolonged lapse in GLP-1 receptor agonist therapy warrants consideration of reinitiation at a reduced dose.

Practitioners should consider starting patients on a reduced dose after a significant therapy lapse.

Incretin agonist therapies improve type 2 diabetes outcomes and cardiovascular mortality.

Incretin agonists may be a viable alternative to surgery for managing diabetes and cardiovascular risks.